| Entry |
|
|---|
| Name |
Taspoglutide (USAN/INN) |
|---|
| Formula |
C152H232N40O45
|
|---|
| Exact mass |
3337.7095
|
|---|
| Mol weight |
3339.71
|
|---|
| Structure |
 |
|---|
| Sequence |
His Aib Glu Gly Thr Phe Thr Ser Asp Val Ser Ser Tyr Leu Glu Gly
Gln Ala Ala Lys Glu Phe Ile Ala Trp Leu Val Lys Aib Arg-NH2
(-CH3 combined: 2; 29) |
|---|
| Type |
Peptide |
|---|
| Class |
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist
|
|---|
| Efficacy |
Antidiabetic, Glucagon-like peptide 1 (GLP-1) receptor agonist |
|---|
| Type |
Modified peptide |
|---|
| Comment |
Glucagon-like peptide 1 (GLP-1) analog [CPD: C16048]
Treatment of type 2 diabetes
|
|---|
| Target |
|
|---|
| Pathway |
| hsa04080 | Neuroactive ligand-receptor interaction |
|
|---|
| Interaction |
|
|---|
| Brite |
Drug groups [BR:br08330]
Antidiabetic agent
DG02044 Hypoglycemic agent
DG01493 GLP-1 receptor agonist
D09723 Taspoglutide
Target-based classification of drugs [BR:br08310]
G Protein-coupled receptors
Secretin receptor family
Glucagon
GLP1R
D09723 Taspoglutide (USAN/INN)
|
|---|
| Other DBs |
|
|---|
| LinkDB |
|
|---|
